薄芝糖肽联合多西他赛和吡柔比星治疗乳腺癌患者的临床价值  

Clinical Value of Bozhi Glycopeptide Injection Combined with Docetaxel and THP in the Treatment of Patients with Breast Cancer

作　　者：于军 YU Jun(Surgical Oncology Department,Donggang Central Hospital,Dandong 118300,China)

机构地区：[1]东港市中心医院肿瘤外科,辽宁丹东118300

出　　处：《中国药物经济学》2021年第10期51-54,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨薄芝糖肽联合多西他赛和吡柔比星(THP)治疗乳腺癌患者的临床价值。方法选取2018年2月至2020年2月在东港市中心医院接受治疗的60例乳腺癌患者作为研究对象,按照随机数字表法分为常规组与试验组,各30例。常规组给予静脉滴注注射用盐酸吡柔比星与多西他赛注射液,而试验组则在常规组的基础上静脉滴注薄芝糖肽注射液,比较两组患者肿瘤细胞凋亡指数、新生血管指标、情绪状态评分、生命质量评分、临床疗效及不良反应发生情况。结果治疗前,两组患者肿瘤细胞凋亡指数、血管内皮生长因子A(VEGFA)、血管内皮生长因子B(VEGFB)及患者焦虑自评量表(SAS)、抑郁自评量表(SDS)、卡氏(KPS)评分比较,差异无统计学意义(P>0.05);治疗后,试验组患者肿瘤细胞凋亡指数、VEGFA、VEGFB优于常规组,差异有统计学意义(P<0.05);治疗后,试验组SAS、SDS、KPS评分优于常规组,差异有统计学意义(P<0.05);试验组患者客观缓解率(ORR)、疾病控制率(CBR)显著高于常规组,差异有统计学意义(P<0.05);试验组不良反应发生率低于常规组,差异有统计学意义(P<0.05)。结论针对乳腺癌患者实施薄芝糖肽联合多西他赛和THP治疗,其疗效显著,有助于调节患者的肿瘤细胞凋亡指数与新生血管指标,提高患者的生命质量,还能够改善患者的情绪状态,并降低引发不良反应发生率。Objective To explore the clinical value of Bozhi glycopeptide combined with docetaxel and pirarubicin(THP) in the treatment of patients with breast cancer. Methods A total of 60 patients with breast cancer admitted to Donggang Central Hospital from February 2018 to February 2020 were selected as the research objects and were divided into a conventional group and a test group according to random number table method, with 30 cases in each group. The conventional group was given intravenous drip of pirarubicin hydrochloride and docetaxel injection, while the test group was given intravenous drip of Bozhi glycopeptide injection plus intravenous drip of pirarubicin hydrochloride and docetaxel injection. The tumor cell apoptosis index,neovascularization index, emotional state score, quality of life score, clinical efficacy and occurrence of adverse reactions were compared between the 2 groups of patients. Results Before treatment, there was no statistically significant difference in tumor cell apoptosis index, VEGFA, VEGFB, SAS, SDS and KPS between the 2 group(P>0.05). After treatment, the tumor cell apoptosis index, vascular endothelial growth factor A(VEGFA), and vascular endothelial growth factor B(VEGFB) of the test group were better than those of the conventional group, and the difference was statistically significant(P<0.05);after treatment, the scores of SAS, self-rating depression scale(SDS), and KPS of the test group were better than those of the conventional group, and the difference was statistically significant(P<0.05);the objective response rate(ORR) and disease control rate(CBR) of the test group was significantly higher than that of the conventional group, and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the test group was lower than that of the routine group, and the difference was statistically significant(P<0.05).Conclusion Bozhi glycopeptide injection combined with docetaxel and pirarubicin(THP) is significantly effective in treating breast cancer patient

关 键 词：薄芝糖肽 多西他赛 吡柔比星 乳腺癌 临床价值 肿瘤细胞凋亡指数 

分 类 号：R737.9[医药卫生—肿瘤] R979.1[医药卫生—临床医学]